Drug Chatter -- Tracking biopharma stock chatter

Profile for Acceleron Pharma Inc. (XLRN)

« Back to company index

XLRN Chatter Timeline

Stock Ticker for XLRN

Most Active Tweeters for XLRN

UserTweets
@j_jccnidan 5
@dispatchtribune 4
@dailypoliticaln 3
@TickerReport 3
@ledgerzette 2

Recent Tweets for XLRN

ConsumerFeed @ConsumerFeed
Acceleron Pharma Inc $XLRN Receives Consensus Rating of “Buy” from Analysts https://t.co/iMOLuIScJh
May 25th 2018, 1:05pm
dakotafinancial @dakotafinancial
Acceleron Pharma Inc $XLRN Expected to Announce Earnings of -$0.64 Per Share https://t.co/vm4xZkUjpX
May 24th 2018, 2:05pm
TheMarketsDaily @TheMarketsDaily
Acceleron Pharma Inc $XLRN Expected to Post Earnings of -$0.64 Per Share https://t.co/vtKcN4pA03
May 24th 2018, 2:05pm
dispatchtribune @dispatchtribune
$3.40 Million in Sales Expected for Acceleron Pharma Inc $XLRN This Quarter https://t.co/HWj5f3HHAy
May 23rd 2018, 4:05am
OlympiaReport @OlympiaReport
Zacks: Brokerages Anticipate Acceleron Pharma Inc $XLRN Will Announce Quarterly Sales of $3.40 Million https://t.co/AjlVOj3Go1
May 23rd 2018, 4:05am
AcceleronPharma @AcceleronPharma
Catch our webcast from the @UBS Global Healthcare Conference today at 1:30pm EDT https://t.co/b5EUlJmIKS $XLRN
May 22nd 2018, 10:05am
j_jccnidan @j_jccnidan
$XLRN Get ready for fireworks
May 22nd 2018, 9:05am
stocknewsdotcom @stocknewsdotcom
$XLRN Begins PULSAR Phase 2 trial which will study sotatercept for the treatment of patients with pulmonary arteri… https://t.co/UCBuyDQTs7
May 22nd 2018, 8:05am
dsobek @dsobek
RT @odibro: $XLRN Announces Initiation of PULSAR Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension https://t.co/TYgVDEEnEl
May 22nd 2018, 7:05am
odibro @odibro
$XLRN Announces Initiation of PULSAR Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension https://t.co/TYgVDEEnEl
May 22nd 2018, 7:05am
JohnsHopkins2 @JohnsHopkins2
@Ogut_Ozgur especially heading into $XLRN data in MDS. Thal is low bar, MDS might trip over
May 21st 2018, 2:05pm
j_jccnidan @j_jccnidan
$XLRN Celgene ruining this stock.
May 21st 2018, 1:05pm
QuantchaIdeas @QuantchaIdeas
Covered Call Alert: ACCELERON PHARMA INC. COMMON S $XLRN returning up to 23.94% through 17-Aug-2018… https://t.co/CXZmU5OGaK
May 21st 2018, 9:05am
j_jccnidan @j_jccnidan
$CELG Celgene owns 15% of $XLRN. With XLRN completing phase 3 on Lustpatercept makes sense for them to acquire them
May 21st 2018, 9:05am
registrarjourn @registrarjourn
-$0.64 EPS Expected for Acceleron Pharma $XLRN This Quarter https://t.co/vzTeFZ3vHM
May 21st 2018, 6:05am
TickerReport @TickerReport
-$0.64 EPS Expected for Acceleron Pharma $XLRN This Quarter https://t.co/zWWRO9ia7F
May 21st 2018, 3:05am
TickerReport @TickerReport
-$0.64 EPS Expected for Acceleron Pharma $XLRN This Quarter https://t.co/aqgjm5y6lE
May 21st 2018, 3:05am
dailypoliticaln @dailypoliticaln
-$0.64 EPS Expected for Acceleron Pharma $XLRN This Quarter https://t.co/yu8hO8zuuN
May 21st 2018, 3:05am
Sports_bios @Sports_bios
@adar170 Who knows.. my tentative mark on the $XLRN Medalist and Believe P3s primary efficacy endpt is a "Y" - the… https://t.co/ZQgdxqngE0
May 19th 2018, 4:05pm
BioWino @BioWino
$xlrn seller seems convinced.
May 18th 2018, 1:05pm
tradnews_ @tradnews_
RT @AlertTrade: UPSIDE MOMENTUM ALERT: $XLRN ACCELERON PHARMA INC COMMON S ? TradeIdeas via https://t.co/VS8RO1bzXJ to Free Trading Room
May 18th 2018, 10:05am
j_jccnidan @j_jccnidan
$XLRN Volume is ramping up BUY
May 18th 2018, 9:05am
Biotech2050 @Biotech2050
RT @tgtxdough: RBC $XLRN – ph2 beta-thal extension data continues to show luspatercept's durable benefits, with additional positive color o…
May 18th 2018, 9:05am
tgtxdough @tgtxdough
RBC $XLRN – ph2 beta-thal extension data continues to show luspatercept's durable benefits, with additional positiv… https://t.co/av55ByIKeM
May 18th 2018, 9:05am
DeepSouthDoctor @DeepSouthDoctor
Is recent $XLRN weakness related to (partner) $CELG repeatedly getting egg on its face for how it's been executing… https://t.co/s0gLfXP93w
May 17th 2018, 11:05am
IlliniJJ @IlliniJJ
$XLRN - To deliver three presentations on luspatercept at the 23rd Congress of the European Hematology Association… https://t.co/z5MtvI8NTd
May 17th 2018, 10:05am
tradnews_ @tradnews_
RT @AlertTrade: DOWNSIDE MOMENTUM ALERT: $XLRN ACCELERON PHARMA INC COMMON S ? TradeIdeas via https://t.co/VS8RO1bzXJ to Free Trading Room
May 16th 2018, 12:05pm
AlertTrade @AlertTrade
DOWNSIDE MOMENTUM ALERT: $XLRN ACCELERON PHARMA INC COMMON S ? TradeIdeas via https://t.co/VS8RO1bzXJ to Free Trading Room
May 16th 2018, 12:05pm
j_jccnidan @j_jccnidan
$XLRN Looking at the chart we are sitting on a big move up....patience
May 16th 2018, 10:05am
4thQuarterCap @4thQuarterCap
Added to $XLRN traders
May 15th 2018, 3:05pm
ZolmaxNews @ZolmaxNews
Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Acceleron Pharma $XLRN Stock Price https://t.co/IMcTf6EnQ6
May 14th 2018, 12:05pm
dailypoliticaln @dailypoliticaln
Acceleron Pharma $XLRN Getting Somewhat Positive Press Coverage, Study Finds https://t.co/Mq4PsqTfTT
May 14th 2018, 12:05pm
Biotech2050 @Biotech2050
RT @tgtxdough: CS $XLRN $CELG investor call with Dr. Joseph Scandura, Attending Physician on the Leukemia Service at Cornell University, to…
May 14th 2018, 11:05am
tgtxdough @tgtxdough
CS $XLRN $CELG investor call with Dr. Joseph Scandura, Attending Physician on the Leukemia Service at Cornell Unive… https://t.co/8eyrpnUTwd
May 14th 2018, 9:05am
QuantchaIdeas @QuantchaIdeas
Covered Call Alert: ACCELERON PHARMA INC. COMMON S $XLRN returning up to 25.45% through 17-Aug-2018… https://t.co/i7QBSp97K4
May 14th 2018, 9:05am
MarketChmln @MarketChmln
$XLRN option volume was 4X normal on Friday with 2,942 contracts. Call volume was 17% and put volume was 83%. https://t.co/dZu4wUEm3F
May 13th 2018, 12:05pm
ThisLincolnian @ThisLincolnian
Q2 2018 EPS Estimates for Acceleron Pharma Boosted by Analyst $XLRN https://t.co/vp97lvGVUJ
May 13th 2018, 6:05am
ledgerzette @ledgerzette
Q2 2018 EPS Estimates for Acceleron Pharma $XLRN Reduced by Leerink Swann https://t.co/HPbmTF7Qub
May 13th 2018, 6:05am
TheMarketsDaily @TheMarketsDaily
Acceleron Pharma $XLRN Price Target Increased to $69.00 by Analysts at HC Wainwright https://t.co/f9y2QU94Zx
May 13th 2018, 3:05am
ZolmaxNews @ZolmaxNews
Acceleron Pharma $XLRN Price Target Increased to $69.00 by Analysts at HC Wainwright https://t.co/QTXMNRSSeg
May 13th 2018, 3:05am
TranscriptDaily @TranscriptDaily
Credit Suisse Group Analysts Give Acceleron Pharma $XLRN a $55.00 Price Target https://t.co/kpd73Qo9nf
May 13th 2018, 3:05am
dispatchtribune @dispatchtribune
Acceleron Pharma $XLRN to Post Q2 2018 Earnings of -$0.57 Per Share, Oppenheimer Forecasts https://t.co/USldUVrT4k
May 13th 2018, 1:05am
TranscriptDaily @TranscriptDaily
Q2 2018 EPS Estimates for Acceleron Pharma $XLRN Reduced by Leerink Swann https://t.co/L67JwNz1h8
May 13th 2018, 1:05am
OlympiaReport @OlympiaReport
Q2 2018 EPS Estimates for Acceleron Pharma Boosted by Analyst $XLRN https://t.co/ySwrfoIG7Z
May 13th 2018, 1:05am
ConsumerFeed @ConsumerFeed
$3.40 Million in Sales Expected for Acceleron Pharma $XLRN This Quarter https://t.co/33SBoCMgPE
May 12th 2018, 9:05pm
EnterpriseLeade @EnterpriseLeade
Credit Suisse Group Analysts Give Acceleron Pharma $XLRN a $55.00 Price Target https://t.co/V2zs1IGI4U
May 12th 2018, 11:05am
dispatchtribune @dispatchtribune
Acceleron Pharma $XLRN Given a $55.00 Price Target by Credit Suisse Group Analysts https://t.co/LfZbXnlEaV
May 12th 2018, 11:05am
WeekHerald @WeekHerald
Acceleron Pharma $XLRN to Post Q2 2018 Earnings of -$0.57 Per Share, Oppenheimer Forecasts https://t.co/nLT1apBiLD
May 12th 2018, 6:05am
ledgerzette @ledgerzette
Acceleron Pharma to Post Q2 2018 Earnings of -$0.62 Per Share, Piper Jaffray Forecasts $XLRN https://t.co/3a4pFcHWuR
May 12th 2018, 6:05am
dakotafinancial @dakotafinancial
Acceleron Pharma $XLRN PT Raised to $69.00 at HC Wainwright https://t.co/vZRVfzLoOo
May 12th 2018, 5:05am

Contact © thinkBiotech LLC 2004 - 2018. All rights reserved.